GAMMA Investing’s AnaptysBio ANAB Stock Holding History

GAMMA Investing’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$28.8K	Buy	574 +127	+28%	+$7.18K	﹤0.01%	2716
2026 Q2	$30.2K	Buy	447 +5	+1%	+$303	﹤0.01%	2610
2026 Q1	$24.5K	Buy	442 +58	+15%	+$3.12K	﹤0.01%	2618
2025 Q4	$18.6K	Buy	384 +35	+10%	+$1.36K	﹤0.01%	2655
2025 Q3	$10.7K	Sell	349 -12	-3%	-$275	﹤0.01%	2852
2025 Q2	$8.01K	Buy	361 +33	+10%	+$691	﹤0.01%	2916
2025 Q1	$6.1K	Buy	+328	New	+$5.47K	﹤0.01%	2999
2024 Q4	–	Sell	-40	Closed	-$1.34K	–	3782
2024 Q3	$1.34K	Buy	40 +4	+11%	+$137	﹤0.01%	3177
2024 Q2	$902	Buy	36 +15	+71%	+$349	﹤0.01%	3083
2024 Q1	$473	Buy	21 +6	+40%	+$142	﹤0.01%	3113
2023 Q4	$354	Buy	+15	New	+$259	﹤0.01%	3027

Other funds holding ANAB

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing's ANAB Position: Q3 2026 in Review

GAMMA Investing increased its AnaptysBio (ANAB) stake by 28% in Q3 2026, buying an estimated $7.18K and bringing the position to 574 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2716.

GAMMA Investing first reported a position in ANAB in Q4 2023 and has held it in 11 quarters since. The position peaked at $30.2K in Q2 2026. 4 funds tracked by Wall St. Rank hold ANAB as of Q3 2026.

GAMMA Investing held 574 shares of AnaptysBio worth $28.8K as of Q3 2026.
GAMMA Investing bought 127 AnaptysBio shares in Q3 2026, an estimated $7.18K.
AnaptysBio made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2716 holding.
GAMMA Investing first reported a position in AnaptysBio in Q4 2023 and has held it in 11 quarters since.
GAMMA Investing's AnaptysBio position peaked at $30.2K in Q2 2026.
4 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.